Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study
Question
Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study
Direct answer
A 77% overall response rate in first-line recurrent disease supports expanded label indications for subcutaneous amivantamab, lifting prospective oncology revenue for JNJ. — bullish pressure on JNJ via pharmaceutical pipeline milestone expansion.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-26
- Revision
- 1 · 2026-10-27
Cite as: Market Ontology, “Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/johnson-johnson-subcutaneous-amivantamab-hits-77-response-rate-in-head-and-neck-fcbe4a
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JNJ | ▲Bull | 1–4 weeks | pharmaceutical pipeline milestone expansion | 72 |
Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck Study
A 77% overall response rate in first-line recurrent disease supports expanded label indications for subcutaneous amivantamab, lifting prospective oncology revenue for JNJ. — bullish pressure on JNJ via pharmaceutical pipeline milestone expansion.
OrigAMI-4 study showed a 77% overall response rate in first-line recurrent head and neck cancer.
- SourceOrigAMI-4 study showed a 77% overall response rate in first-line recurrent head and neck cancer.
- TransmissionA 77% overall response rate in first-line recurrent disease supports expanded label indications for subcutaneous amivantamab, lifting prospective oncology revenue for JNJ.
- SummaryJohnson & Johnson reported Phase 1b/2 data for subcutaneous amivantamab in advanced head and neck cancer. The combination with pembrolizumab and chemotherapy yielded a 77% overall response rate. The finding strengthens Johnson & Johnson's oncology pipeline in high-unmet-need squamous cell indications.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullish | 266.30 2026-10-26 | Pending | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer TrialJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.